COT 143
Alternative Names: COT-143; RESP X – Infex Therapeutics; RESP-XLatest Information Update: 16 May 2025
At a glance
- Originator Shionogi
- Developer Infex Therapeutics; Shionogi
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action PcrV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pseudomonal infections
Most Recent Events
- 07 Sep 2024 Pharmacodynamics, adverse events and pharmacokinetics data from phase-I clinical trials in Pseudomonal infections presented at the 34th Annual Congress of the European Respiratory Society (ERS-2024)
- 28 May 2022 No recent reports of development identified for preclinical development in Pseudomonal-infections in Japan (IV)
- 22 Jul 2019 The AMR Centre plans phase I and phase II trials for Pseudomonal infections in 2020